Forma Therapeutics Holdings Inc
1 day chart
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
Buy US stocks in Australia with $0 brokerage and trade FMTX today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.